Aclarion, Inc. (ACON) experienced a 10% increase in its stock price Tuesday following the news of securing complete funding for its crucial CLARITY trial. Currently, ACON's stock is trading at $7.16, an increment of $0.51 from its previous closing price of $6.65. Throughout the day, the stock fluctuated between a high of $8.75 and a low of $6.75. Remarkable trading activity was observed with a volume of 6.61 million shares, far surpassing the average volume of 185,599 shares.
The objective of the trial is to highlight the clinical and economic advantages of Nociscan—an AI-driven biomarker technology by Aclarion—which aids physicians in accurately diagnosing the source of chronic low back pain. Securing funding for the CLARITY trial represents a significant progression for Aclarion as it aims to substantiate the role of Nociscan in decision-making for spine surgeries.
